Personalized Gene Therapy Treatment Market Report 2025

The personalized gene therapy treatment market size has grown exponentially in recent years. It will grow from $6.93 billion in 2024 to $8.38 billion in 2025 at a compound annual growth rate (CAGR) of 20.8%. The growth during the historic period is driven by the increasing prevalence of genetic disorders, progress in gene editing technologies, rising awareness of personalized medicine, supportive government initiatives and funding, and expansion of biotechnology research and infrastructure.

The personalized gene therapy treatment market size is expected to see exponential growth in the next few years. It will grow to $17.65 billion in 2029 at a compound annual growth rate (CAGR) of 20.5%. The growth during the forecast period is fueled by the expansion of clinical trials for gene therapies, the integration of artificial intelligence and predictive analytics in treatment design, increasing collaborations between pharmaceutical and biotechnology companies, the development of safer and more efficient delivery vectors, and the rising demand for targeted and precision therapies. The primary trends in the forecast period include integration of artificial intelligence and machine learning in therapy design, expansion of genomic sequencing capabilities, growth in collaborations between biotechnology and pharmaceutical companies, automation in gene therapy manufacturing processes, and adoption of blockchain technology for genetic data security.

The increasing prevalence of genetic disorders is expected to drive the growth of the personalized gene therapy treatment market. Genetic disorders arise from DNA abnormalities that disrupt normal bodily functions, and their prevalence is rising due to factors such as increasing parental age, where older reproductive cells carry a higher risk of passing mutations to offspring. Personalized gene therapy offers a solution by directly correcting the faulty genes responsible for the condition and customizing treatment based on an individual’s genetic profile. This approach enhances the efficacy of treatment and reduces side effects. For example, in September 2023, the Cystic Fibrosis Trust reported that the number of cystic fibrosis (CF) patients in the UK increased to 11,148 in 2022, up from 10,908 in 2021. As a result, the growing prevalence of genetic disorders is contributing to the expansion of the personalized gene therapy treatment market.

Key players in the personalized gene therapy treatment market are focusing on strategic partnerships to enhance their technological capabilities and accelerate the delivery of innovative therapies. These partnerships allow companies to combine resources and expertise, sharing both the risks and rewards of new developments. For example, in May 2025, Aldevron, a US-based company specializing in the production of DNA, RNA, and proteins, partnered with Integrated DNA Technologies, a US-based provider of genomics solutions, to create the world’s first mRNA-based personalized CRISPR therapy for a rare and life-threatening genetic condition called urea cycle disorder (UCD). This “N of 1” therapy was developed in just six months, incorporating a custom guide RNA, mRNA-encoded base editor, off-target safety services, and a clinically validated lipid nanoparticle delivery system. The success of this therapy represents a significant milestone in personalized in vivo base-editing treatments.

In July 2025, Eli Lilly and Company, a US-based pharmaceutical company, acquired Verve Therapeutics Inc. for $1.3 billion. This acquisition allows Eli Lilly to expand its gene-editing portfolio into cardiovascular diseases and strengthens its position in the personalized gene therapy market. Verve Therapeutics, a clinical-stage company, is focused on developing one-time base-editing gene therapies specifically for cardiovascular conditions.

Major players in the personalized gene therapy treatment market are Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Kyowa Kirin Co. Ltd., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Rocket Pharmaceuticals Inc., REGENXBIO Inc., Intellia Therapeutics Inc., Beam Therapeutics Inc., Adaptimmune Therapeutics plc, Krystal Biotech Inc., Miltenyi Biomedicine GmbH, Bluebird Bio Inc., uniQure N.V., Mesoblast Limited, Astellas Gene Therapies Inc., Adverum Biotechnologies Inc., Autolus Therapeutics plc.

North America was the largest region in the personalized gene therapy treatment market in 2024. The regions covered in personalized gene therapy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the personalized gene therapy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Personalized gene therapy treatment refers to specialized medical care that delivers targeted therapies tailored to an individual’s unique genetic profile. It involves modifying, repairing, or replacing faulty genes to directly address the root causes of genetic disorders. Personalized gene therapy treatment improves precision of care, reduces the risk of adverse effects, and enhances overall therapeutic outcomes.

The primary types of personalized gene therapy treatments include targeted treatments and pharmacogenomics. Targeted treatments are therapies specifically designed to modify or regulate particular genes linked to a disease in order to maximize therapeutic benefit while minimizing side effects. The vector types include viral and nonviral approaches and are administered through various distribution channels such as hospitals, clinics, home administration, and others. These treatments are applied across diverse medical areas, including oncology, neurology, hematology, infectious diseases, ophthalmology, and more.

The personalized gene therapy treatments market research report is one of a series of new reports that provides personalized gene therapy treatments market statistics, including personalized gene therapy treatments industry global market size, regional shares, competitors with a personalized gene therapy treatments market share, detailed personalized gene therapy treatments market segments, market trends and opportunities, and any further data you may need to thrive in the personalized gene therapy treatments industry. The personalized gene therapy treatments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The personalized gene therapy treatment market consists of revenues earned by entities by providing services such as genetic testing and diagnostics, personalized therapy design, gene editing treatments, viral and non-viral vector delivery, patient-specific cell therapies, and post-treatment monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized gene therapy treatment market also includes sales of viral vectors, gene editing platforms, cell culture systems, bioprocessing tools, and monitoring software. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.